Research Analysts Issue Forecasts for MRKR FY2026 Earnings
Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) – Brookline Capital Management issued their FY2026 earnings estimates for Marker Therapeutics in a report released on Monday, March 31st. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of ($5.15) for the year. Brookline Capital Management currently has a “Strong-Buy” rating […]
Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) – Brookline Capital Management issued their FY2026 earnings estimates for Marker Therapeutics in a report released on Monday, March 31st. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of ($5.15) for the year. Brookline Capital Management currently has a “Strong-Buy” rating […]
